Concurrent immunotherapy and re‐irradiation utilizing stereotactic body radiotherapy for recurrent high‐grade gliomas

BACKGROUND: Clinical trials evaluating immune checkpoint inhibition (ICI) in recurrent high‐grade gliomas (rHGG) report 7%–20% 6‐month progression‐free survival (PFS), while re‐irradiation demonstrates 28%–39% 6‐month PFS. AIMS: We evaluate outcomes of patients treated with ICI and concurrent re‐irr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahase, Sean S., Roytman, Michelle, Roth O'Brien, Diana, Ivanidze, Jana, Schwartz, Theodore H., Pannullo, Susan C., Ramakrishna, Rohan, Magge, Rajiv S., Williams, Nicholas, Fine, Howard A., Chiang, Gloria Chia‐Yi, Knisely, Jonathan P. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363830/
https://www.ncbi.nlm.nih.gov/pubmed/36750401
http://dx.doi.org/10.1002/cnr2.1788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363830/
https://www.ncbi.nlm.nih.gov/pubmed/36750401
http://dx.doi.org/10.1002/cnr2.1788

Ejemplares similares